Results 31 to 40 of about 6,879 (203)
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad +4 more
wiley +1 more source
In this study, we assessed the feasibility of using positron emission tomography (PET) and the tracer [ 11 C]OMAR ([ 11 C]JHU75528), an analogue of rimonabant, to study the brain cannabinoid type 1 (CB1) receptor system.
Raúl Herance +10 more
doaj +1 more source
Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. [PDF]
Previous research has shown that academic physicians conflicted by funding from the pharmaceutical industry have corrupted evidence based medicine and helped enlarge the market for drugs.
John M McPartland
doaj +1 more source
Pharmacological blockade of the cannabinoid type 1 receptor, a G protein-coupled receptor expressed in the central nervous system and various peripheral tissues, reverses diet-induced obesity and dyslipidemia through the reduction of food intake and ...
Robin van Eenige +10 more
doaj +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Recent lines of experimental evidence have indicated that saikosaponin A (SSA)—a bioactive ingredient of the medicinal plant, Bupleurum falcatum L.—potently and effectively reduced operant self-administration of chocolate and reinstatement of chocolate ...
Paola Maccioni +7 more
doaj +1 more source
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux +26 more
wiley +1 more source
Rimonabant-induced catatonia in schizophrenia: A case report
Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease.
Sivakumar, Palanimuthu T. +7 more
core +1 more source
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. [PDF]
peer reviewedAIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year.
Rissanen, Aila M +9 more
core +1 more source
The dynamics of neuronal microtubules are essential for brain plasticity. Vesicular transport and synaptic transmission, additionally, requires acetylation of α-tubulin, and aberrant tubulin acetylation and neurobiological deficits are associated ...
Jordi Tomas-Roig +4 more
doaj +2 more sources

